In 2003, Hastak and colleagues conducted a study in which they discovered that EGCG has the capability to initiate apoptosis progression in human prostate cancer cell lines by activating p53 and inhibiting the NF-kB pathway. The gene discussed is TP53; the disease is prostate carcinoma.